Duloxetine
Duloxetine. Balanced SERT + NET inhibition across the dose range (unlike venlafaxine's dose-dependent NE addition). Broader pain indications as a… Oral half-life 13 h.
Balanced SERT + NET inhibition across the dose range (unlike venlafaxine's dose-dependent NE addition). Broader pain indications as a result.
PK: THE SOUNDEST ARITHMETIC IN ITS GROUP, AND THE FIX IS DOCUMENTATION. V 940 L is not in any abstract and looks like the class-6 defect; it is the INVERSE of it. It is the cited paper verbatim 60 mg-arm apparent volume of 1879.74 L MULTIPLIED BY F — the correct correction, since the solver divides by a true volume — and the resulting clearance of 100.2 L/h matches the paper published 98.41 to within 2%. Nothing in the record said so, which is exactly how such a value gets un-corrected by a later pass; it is written down here. The half-life is the 30 mg arm alone, rounded up, and sits ABOVE this record own reference range of "approximately 10-12 hours". F 0.5 is the label figure, stated in no primary. ka 0.4 IS BACK-DERIVED AND STRUCTURALLY IMPOSSIBLE: it implies a 5.81 h peak against measured values of 6.83, 6.10 and 6.60 h, and duloxetine is ENTERIC-COATED with a roughly two-hour lag that no single first-order rate can represent — THE SCHEMA HAS NO LAG PARAMETER, so this cannot be fixed by re-sourcing. Both occupancy rows verify.
Pharmacokinetics
- Oral — t½ 12.9 h · F 50% · Vd 940 L
Sources: PMID:21366359, PMID:16506079, PMID:11750180, PMID:10664922